Pepceuticals

Pepceuticals, established in 1998, is a specialist manufacturer of synthetic peptides and a supplier of polyclonal and monoclonal antibodies. The company serves the life sciences industry and academic institutions globally. Its primary business involves contract manufacturing of custom synthetic peptides, including complex and modified molecules, for various research applications. Pepceuticals offers a comprehensive drug development program, providing peptides from pre-GMP research stages through to cGMP manufacturing in quantities ranging from milligrams to kilograms. The company's services also include the provision of peptide synthesis reagents, peptide libraries, and various peptide modifications such as labeling and conjugation.

Founded in the UK, Pepceuticals operates from a purpose-built facility in Leicestershire, which includes advanced research and development labs and cGMP-grade manufacturing suites. The company holds certifications from the MHRA for GMP API and is ISO 9001-2015 accredited. On September 25, 2023, Pepceuticals was acquired by Biosynth, a global supplier of critical materials to the life science industry. This acquisition integrated Pepceuticals' expertise in large-scale GMP peptide production and fill-finish capabilities into Biosynth's broader portfolio, aiming to provide an end-to-end service for customers from clinical trials to commercial supply. Dr. Kamal Badiani was the Managing Director of Pepceuticals at the time of the acquisition.

Keywords: synthetic peptides, custom peptide synthesis, monoclonal antibodies, polyclonal antibodies, GMP manufacturing, peptide reagents, life sciences, drug development, peptide libraries, cGMP peptides, active pharmaceutical ingredients, API manufacturing, peptide therapeutics, bioconjugation, contract manufacturing, pre-GMP research, fill-finish services, laboratory reagents, chemical synthesis, pharmaceutical industry